Michael McKelvey, Ph.D., has been appointed president, inVentiv Health Clinical Division and executive vice president, inVentiv Health. Dr. McKelvey has extensive experience in the CRO industry and a strong background in clinical development, technology and the development of industry strategies.
 
Dr. McKelvey previously served as executive vice president and chief operating officer at Aptiv Solutions, which was acquired by ICON in 2014. Prior to Aptiv Solutions, he was president and chief executive officer and a board member of eResearchTechnology, Inc. (ERT). Dr. McKelvey also led PAREXEL’s Phase II-IV clinical operations for the Americas, as well as their global data management and global biostatistics groups.
 
“Mike McKelvey has proven himself to be a hands-on leader who builds dynamic teams to tackle some of the most critical drug development issues facing the industry,” said Jeffrey P. McMullen, Chairman, inVentiv Health Clinical Division and Vice Chairman, inVentiv Health. “His vision is to incorporate innovation into the current drug development process by providing clients with an outsourcing model that embeds both clinical and commercial services.”